Robin Neely Prince

Learn More
Heparin-binding EGF-like growth factor (HB-EGF) is a ligand for EGF receptor (EGFR) and possesses the ability to signal in juxtacrine, autocrine and/or paracrine mode, with these alternatives being governed by the degree of proteolytic release of the ligand. Although the spatial range of diffusion of released HB-EGF is restricted by binding heparan-sulfate(More)
The ErbB receptor family is dysregulated in many cancers, and its therapeutic manipulation by targeted antibodies and kinase inhibitors has resulted in effective chemotherapies. However, many malignancies remain refractory to current interventions. We describe a new approach that directs ErbB receptor interactions, resulting in biased signaling and(More)
Our ability to engineer organisms with new biosynthetic pathways and genetic circuits is limited by the availability of protein characterization data and the cost of synthetic DNA. With new tools for reading and writing DNA, there are opportunities for scalable assays that more efficiently and cost effectively mine for biochemical protein characteristics.(More)
Growth factor signaling can affect tissue remodeling through autocrine and paracrine mechanisms. Recent evidence indicates that hypertrophic signaling in cardiomyocytes is induced through transactivation of the epidermal growth factor (EGF) receptor by heparin-binding EGF (HB-EGF). Here it is shown that HB-EGF operates in a spatially restricted local(More)
  • 1